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Objectives
After completion of this program, the reader should be able to:
1. Describe typical symptoms and duration of Zika virus infection.
2. Explain how Guillain-Barre syndrome and microcephaly affect the nervous system.
3. Recognize the most common neonatal neurological
disorders associated with a maternal Zika virus infection during pregnancy.
4. Identify available screening tests and therapies to
manage conditions associated with long-term Zika
virus effects.
5. List preventive measures taken to decrease the
spread ofZika virus.
Abstract
Zika virus is a public health emergency of international concern. Zika virus (ZIKV) is a mosquito-borne pathogen that is
carried by the Aedes genus. Zika is spread through direct bite
and nonvector transmission. Most individuals infected with
Zika will be asymptomatic, but some may present nonspecific
viral symptoms. A rising number of neurological disorders in
newborns whose mothers were infected with ZIKV during
pregnancy have been reported due to recent outbreaks. Neurological disorders affect both the central and peripheral
nervous systems and can result from bacterial, viral, fungal
or parasitic infections of the nervous system or from the immune response to the infection. Guillain-Barre and microcephaly are two complications that can occur due to ZIKV
infection. Recent studies have shown there is a stronger correlation between a maternal ZIKV infection during her first
trimester of pregnancy and neurological disorders in the neonate. Currently, there is not an available treatment option to
change the physical appearance of microcephaly or reverse
·the complications from Zika virus. However, there are developmental screenings and therapies that can be performed to
detect and improve strength and movement needed to perform daily tasks. Precautions, such as mosquito repellents
and protective clothing, should be taken to avoid exposure.
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Women should wait the appropriate time lengths and be:
tested along with their partner, regardless of symptom sta- ·
tus, before attempting pregnancy. Available tests include'
real-time reverse transcription-polymerase chain reaction :
(rRT-PCR), which is U.S. Food and Drug Administration!
(FDA) approved and considered the standard test, immuno- ·
globulin (IgM), and plaque reduction neutralization test :
(PRNT). A combination of these tests will produce the most :
accurate results.
Key Terms
Aedes; Fetus; Microcephaly; Pregnancy Trimester First; Zika
Virus
Introduction
Zika virus is a mosquito-borne pathogen that is carried by
the Aedes genus. In tropical regions the Aedes aegypti is the
carrier. In temperate regions the carrier is Aedes albopictus.
The Aedes genus also carries dengue fever, chikungunya and
yellow fever viruses.1 Transmission of Zika virus (ZIKV) occurs through direct bite. N onvector transmission primarily
involves sexual routes, specifically from symptomatic men to
partners, perinatal and blood transfusion. At this time, there
is no evidence to support transmission through urine, saliva,
breastfeeding or respiratory droplets. Zika virus has an incubation period that has been estimated to be four to seven
days. Most individuals infected with the virus are asymptomatic. Infected individuals who are symptomatic typically
experience nonspecific viral symptoms such as arthralgia,
myalgia, headache, malaise, rash and nonpurulent conjunctivitis that have a two to seven day duration. More serious
complications that have been reported include birth defects
and long-term neurological complications.2
Zika is a flavivirus consisting of single stranded, positive ribonucleic acid (RNA). The Flaviviridae family includes other
human pathogens including dengue, West Nile, yellow fever,
tick-borne encephalitis and Japanese encephalitis virus.3 The
virus is a 50 nm spherical virion that comprises three structural proteins. It is believed to form one serotype with two
main lineages: African and Asian. Outbreaks in the United
States have been traced back to the Asian lineage. The Asian
lineage has been associated with NSl codon usage making it
better adaptable to humans. The African lineage transmission is sylvatic and has not been associated with symptoms.4
The virus isolate enters human dermal fibroblasts, epidermal
keratinocytes and immature dendritic cells.3 The initial immune receptor is the Toll Like Receptor 3 (TLR-3) which detects the infection in human fibroblasts. The activation of
TLR-3 pathways in central nervous system (CNS) cells may
trigger apoptosis and attenuate neurogenesis, directly con-
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tributing to fetal neuropathology.s Transplacental delivery to
fetus may occur by infection of the cytotrophoblasts or transmigration of infected primary human placental macrophages.3

Neurological Introduction
With the recent outbreak of ZIKV there has been a rise in
neurological disorders reported in newborns whose mothers
were infected with ZIKV during their pregnancy.6 Neurological disorders affect the central and peripheral nervous systems; this includes the brain, spinal cord, muscles, nerve
roots, autonomic nervous system, peripheral nerves, cranial
nerves and neuromuscular junctions. The presentation of
these disorders varies based on the causative agents and
what part of the nervous system is affected. Neurological
disorders can result from bacterial, viral, fungal or parasitic
infections of the nervous system from the host immune response to the infection. The most common bacterial causes of
neurological disorders are Mycobacterial tuberculosis and
Neisseria meningitides. The most common fungal infections
are Cryptococcus and Aspergillus. Malaria and Chagas are the
result of parasitic infections. Lastly, the viruses that can
cause neurological disorders are human immunodeficiency
virus (HIV), Enteroviruses, West Nile virus, and Zika virus.
When a pregnant mother contracts a ZIKV infection there is a
risk her unborn child will develop neurological complications. These neurological complications include GuillainBarre syndrome, encephalitis, meningoencephalitis, facial
paralysis, myelitis and microcephaly,7.B Currently there is
little information on the effects of a mild or asymptomatic
ZIKV infection during early pregnancy. The risk of a fetus
developing a neurological complication is higher when a
pregnant woman experiences a symptomatic ZIKV infection.9
While a ZIKV infection can cause all of the neurological com-

plications mentioned above, it has been observed to most
commonly cause Guillain-Barre and microcephaly.

Guillain-Barre
In some cases of Zika there are more serious clinical outcomes reported, including Guillain-Barre syndrome. GuillainBarre syndrome is an autoimmune and neurological disease,
in which the body's immune system attacks the peripheral
nervous system. 7 The syndrome can affect the nerves that control muscle movement as well as those that transmit feelings
of pain, temperature and touch. This can result in muscle
weakness and loss of sensation in the legs and arms. GuillainBarre syndrome is triggered by previous infections, typically
respiratory or gastrointestinal. Other viruses that have been
associated with Guillain-Barre include dengue fever and
chikungunya. Guillain-Barre syndrome is not thought to be
mediated by antiglycolipid antibodies but is thought to be
introduced by neurotoxic factors associated with Zika. The
acute phase of Guillain-Barre syndrome is treated with either
plasmapheresis or intravenous immunoglobulin and supportive care. The recovery phase typically lasts from six to
twelve months but may take up to three years for some patients.10 Approximately 80 percent of patients can walk independently six months after diagnosis, and 60 percent fully
recover motor strength one year after diagnosis.
Microcephaly
Microcephaly is a birth defect where the newborn's head has
a significant degree of reduction in the circumference when
compared to other newborns of the same sex and age. The
smaller head circumference is a direct result of microcephaly, that is, smaller brains, which did not develop properly,
and can lead to impairment in motor, sensory and cognitive
functions.11. 12 Figure 1 compares an infant with a normally

Figure 1. Comparison of Normally Developed Head to Varying Severities ofMicrocephaly in lnfant. 13
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developed head to infants with varying severities of
microcephaly.u Microcephaly is a result of a decrease in the
number of cell divisions in the brain during fetal development, resulting in a decrease in production offunctional neurons.12 A large number of various case reports and studies
illustrate a strong correlation between a ZIKV infection in the
pregnant mother and the development of microcephaly in
the developing baby.s.12,14
A study by Frietas et al. looked at the overall incidence of

ZIKV infections in pregnant mothers and the risk of microcephaly.a The results of their investigation showed that more
than one million people have been infected with ZIKV since
its endemic onset in April 2015. They also uncovered an unusual increase in the number of newborns with microcephaly
six months after the onset of the endemic. In 2015 there
were 1,248 new cases of microcephaly registered, which corresponded to 99. 7 cases per 100,000 live births. This
incidence represents a twentyfold increase in microcephaly
cases when compared to recent years. This finding helps confirm that the increase in microcephaly cases is due to the
current ongoing ZIKV endemic.
Studies about Zika and the Risk of Various Birth Defects
A preliminary report conducted by Pacheco et al. investigated the ZIKV outbreak in Colombia by using the national public health surveillance system of the Colombian Instituto
Nacional de Salud (INS).14 This surveillance system serves to
collect information for notifiable conditions like dengue,
chikungunya, ZIKV, acute flaccid paralysis and congenital
defects. The results of reported diseases are published by INS
weekly. Patients met inclusion criteria for the study if they
had clinical symptoms with or without laboratory confirmation of ZIKV from Aug. 9, 2015, to April 2, 2016. At the time of
this study, data collection was still ongoing for the majority
of the patients in this group. The researchers performed a
subgroup analysis which included the 1,850 patients who
had already delivered their babies. All of the patients in the
subgroup analysis also reported during which week in their
pregnancy they noticed the onset of ZIKV symptoms. In this
subgroup, 532 patients became infected during the first trimester, 702 in the second trimester and 616 in the third trimester. For the group of women who were diagnosed with
ZIKV in the third trimester, 82 percent of the children were
born with a normal birth weight without any neurological
disorders. The remaining 18 percent of children born to
women diagnosed with ZIKV during the third trimester fell
into the following categories: 2 percent were born with a low
birth weight, 8 percent were born preterm, 1 percent died
during the perinatal period. The remaining 7 percent were
still being followed at the time the study was published.
There were no reported cases of microcephaly or brain abnormalities in any of the children whose mothers contracted
ZIKV during the third trimester of pregnancy.
This study also utilized the INS to look for cases of reported
microcephaly. From Jan. 1, 2016, until April 28, 2016, a total
of 50 infants were reported to the INS for possible microcephaly. Currently the causes of 26 of the cases are still being
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investigated. 14 Twenty cases had identifiable causes that
were not related to ZIKV and were determined to have been
caused by syphilis, toxoplasmosis, rubella, cytomegalovirus
and herpes (STORCH) infections, genetic causes or neural
tube defects. These 20 children also had negative results of
the diagnostic ZIKV RNA reverse transcriptase polymerase
chain reaction (RT-PCR) test. The final four infants had microcephaly caused by an asymptomatic ZIKV infection in the
mother evidenced by a positive RT-PCR assay, negative
STORCH evaluation and normal karyotypes.
Another study conducted by Tang discussed the current evidence linking ZIKV infections as a causative agent for microcephaly.12 This study reviewed previous ZIKV outbreaks with
cases from Bahia and a retrospective study from French Polynesia. It was shown with population level data analyses that
there is a strong association between the pregnant mother
contracting the ZIKV infection during the first trimester, or
the first 12 weeks of pregnancy, and an increased risk of microcephaly in neonates as opposed to being infected during
the second or third trimester.12,15 The second trimester consists of weeks 13 to 28, and the third trimester is from the
29th to the 40th week.15 A second study by Johansson et al.
confirmed this association when they evaluated the ZIKV and
the risk of microcephaly in neonates.9 They found that the
risk of inducing neurological disorders in the fetus was the
highest with infection during the first trimester. This study
also discovered there is a negligible risk between a ZIKV infection in the second and third trimesters and microcephaly
development in the neonate.
The study by Tang further discovered that some infants
whose mothers had been infected with ZIKV during their
first trimester of pregnancy presented with macular atrophy
and a decreased cephalic diameter.12 This finding was supported by a study done by Frietas et al. which followed 29
mothers who had a confirmed diagnosis of ZIKV while pregnant and gave birth to a newborn with microcephaly. Of the
29 newborns, 10 were found to have ocular abnormalities.
These abnormalities included focal pigment mottling, chorioretinal atrophy especially in the macular area and optic disc
abnormalities. It is important to note that the mothers did
not have any kind of ocular disturbance or conjunctivitis during their pregnancy.a
Treatment Options for Long-Term Effects of Zika Virus
Microcephaly is one of the most concerning effects of Zika
virus; however, there is no treatment that will change the
physical appearance, enlarge the infant's head or reverse the
possible complications it can cause.16 Soon after the infant is
born, developmental screenings should be performed at each
health care visit. Developmental milestones, growth, sleep,
irritability and abnormal movements should all be monitored and reported to the health care provider. A comprehensive eye exam should be performed within one month of
birth, and additional vision screenings should be addressed
at each follow-up visit. Auditory brainstem responses should
be performed within one month of birth and then again at
four to six months.17
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Available treatments focus on ways to manage conditions
that stem from the microcephaly. Early childhood intervention programs that include speech, physical and occupational
therapy may help patients strengthen abilities.t6 These therapies may improve strength, movement, confidence to perform daily tasks, language skills and even self-esteem issues
associated with the condition.is Some cases of microcephaly
can lead to serious learning and speech disabilities, difficulties with neurological functions and physical complications
like seizures and facial deformities. If seizures occur, they
may be treated with pharmacologic interventions.
Zika and Public Health
According to the Centers for Disease Control and Prevention
(CDC), Zika virus is a public health emergency of international concern. As of Sept. 7, 2016, there have been 671 cases of
pregnant women with evidence of Zika virus in the United
States alone. 19 Since a vaccine to prevent infection of Zika
virus is not currently available, all populations should take
precautions to avoid mosquito bites during the day and
night. This can include wearing long sleeves and pants, using
mosquito repellents (those with DEET or permethrin) and
preventing mosquitos from entering the home by using
screens on windows and doors. Zika can be spread through
intercourse with an infected partner; therefore, male condoms should be used to reduce the risk of acquiring the virus. There are greater central nervous system (CNS) concerns for certain populations, such as women who are either
attempting to become pregnant or are presently pregnant;
therefore, these women should be tested for Zika virus if a
possible exposure has occurred. Women with diagnosed Zika
virus and asymptomatic women with a possible exposure
should wait at least eight weeks from symptom onset
(symptomatic) or Zika virus exposure (asymptomatic) before attempting pregnancy. Regardless of symptom status,
men with a possible Zika virus exposure should wait at least
six months after exposure or symptom onset before attempting pregnancy with their partner.20, 21
The U.S. Food and Drug Administration (FDA) has approved
real-time reverse transcription-polymerase chain reaction
(rRT-PCR) and considers it the standard test to detect Zika
virus. Other tests include assessing immunoglobulin (IgM)
levels and a plaque reduction neutralization test (PRNT). It is
recommended that a combination of these tests be done for
the most accurate results. In pregnant women with a possible Zika exposure, it is recommended that a prenatal ultrasound be performed, regardless of laboratory test results.21
Many of these tests require a blood or urine sample and
must be performed at a CDC center, state or federal health
institution or commercial laboratory. Because the presentation of Zika virus is nonspecific and may be mistaken for other viral infections, a quick and reliable diagnostic test is
needed that could be used in less-developed areas where
Zika virus is more prevalent and access to diagnostic laboratory equipment is limited. Studies are being conducted to
evaluate the effectiveness of a highly sensitive reversetranscription loop-mediated, isothermal amplification (RTLAMP) assay for the detection of Zika as a point-of-care test
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cassette for patients.22
To date, there have been no confirmed blood transfusiontransmission cases in the United States. However, because
there is a strong possibility that Zika may be transmitted
through blood, the FDA recommends that whole blood and
blood components be screened for the virus once a licensed
test becomes available.21, 23
To gather and centralize data to understand more about the
risks of Zika virus during pregnancy, the CDC established the
US Zika Pregnancy Registry and is collaborating with health
care professionals at the state, tribal, local and territorial
levels. The registry is an active surveillance system that
keeps track of pregnant women with laboratory evidence of
confirmed Zika virus and pregnant women with a possible
infection from confirmed exposure in the United States and
its territories. It also includes weekly reporting of the number of women followed in the registry. The CDC encourages
patients to submit information after birth as well. All of the
information collected in the registry will be used to update
recommendations for diagnostic testing, monitoring, counseling and therapy.21.2 4,2s The CDC has also established Zika
Active Pregnancy Surveillance System (ZAPSS) which includes Puerto Rico.26
Conclusion
Zika virus epidemic has raised concerns for health care providers worldwide. The quick transmission from mosquito to
human and lack of consistent symptoms make the infection
difficult to diagnose. Neurological disorders that result from
the virus can range from mild to life-threatening. The largest
concern arises from pregnant mothers due to interruption of
fetal development, especially in the first trimester. Although
there are currently no available treatment options for the
neurological defects of ZIKV on infants, screening tests and
therapies to manage the conditions are available. Caution
should be taken by all populations and multiple tests should
be performed to receive the most accurate diagnosis after
exposure. In order to understand more details about ZIKV,
the CDC has established registries and surveillance systems
for high risk populations such as pregnant women. These
programs will help shape future guidelines and initiatives to
prevent Zika infections and long-term complications.
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Assessment Questions
1.

2.

Which of the following patients should be screened for
Zika?
A. A young woman presenting with fever and tiredness who recently attended the Olympics in Rio.
8. An elderly man from Indonesia who is complaining of a rash and nonpurulent conjunctivitis.
C. A pregnant woman living in Florida who is
asymptomatic .
D. All of the above.
E. A&B.
Zika virus has an incubation period of _
symptom duration of_ days.

7.

For children born with possible microcephaly, how soon
should a comprehensive eye exam and auditory brainstem response test be performed?
A. At month 2
B. Within the first month
C. Within the first year
D. At month 6

8.

Studies are being conducted to evaluate the effectiveness
of a highly sensitive reverse-transcription loopmediated, isothermal amplification (RT-LAMP) assay.
How would this test, if available, be administered?
A. Point-of-care cassette
B. Laboratory blood draw
C. Physician administered POC
D. Self-administered saliva swab

9.

Asymptomatic women with diagnosis or possible exposure of Zika virus should wait
from symptom
onset before attempting pregnancy, and men regardless
of symptom status with a possible exposure to Zika virus, should wait
before attempting pregnancy
with their partner.
A. 2 weeks, 1 week
8. 1 year, 6 months
C. 8 weeks, 6 months
D. 6 months, 8 weeks

days and a

A. 2-7,4-7
8. 4-7, 2-7

c. 3-5, 9-13
D.

1-4,6-10

3.

Guillain-Barre syndrome is thought to be
A. Mediated by antiglycolipid antibodies
B. Introduced by Zika associated neurotoxic factors
C. Associated with memory loss
D. Treated with statin therapy

4.

True or False: Microcephaly is a result of a decrease in
the number of cell divisions in the brain during fetal
development resulting in a decrease in production of
functional neurons which leads to motor, sensory and
cognitive impairments later in life.
A. True
8. False

5.

Current studies show a maternal ZIKV infection during
the_ trimester(s) is more likely to result in children
born with microcephaly.
A. Third
B. Second
C. First
D. A&B
E. B&C
F. All of the above.

6. All of the following are neurological disorders associated
with a ZIKV infection except:
A. Macular atrophy
B. Microcephaly
C. Neuroinfections
D. Guillain-Barre syndrome
E. Meningoencephalitis

12

10. Which of the following test(s) is/are currently available
to detect Zika virus?
A. Real-time reverse transcription-polymerase
chain reaction (rRT-PCR)
B. Immunoglobulin (IgM)
C. Plaque reduction neutralization test (PRNT)
D. Two of the above
E. All of the above
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